Get started
Microsoft - A Little Lower And Much Higher!Microsoft ( NASDAQ:MSFT ) is about to retest strong support: Click chart above to see the detailed analysis👆🏻 In mid 2024 Microsoft perfectly retested the previous channel resistance trendline and the recent weakness has not been unexpected at all. However the overall trend still remains rather bullish and if Microsoft retests the previous all time high, a significant move will most likely follow. Levels to watch: $350 Keep your long term vision! Philip (BasicTrading)
NASDAQ:MSFTLong
by basictradingtv
4
NVIDIA The chance to buy for $230 is NOWNVIDIA is forming a Double Bottom on a 1day RSI bullish divergence, same kind it did on the October 31st 2023 low. The prevailing pattern is a Channel Up and the double bottom could technically kick start the new bullish wave. The last one almost reached the 5.0 Fibonacci extension before pulling back under the 1day MA50. Best opportunity to buy in 2025. Target just under the 5.0 Fib at $230. Follow us, like the idea and leave a comment below!!
NASDAQ:NVDALong
by TheCryptagon
1
EXXON MOBIL: This strong rally won't end any time soon.Exxon Mobil is about to turn overbought on its 1D technical outlook (RSI = 67.390, MACD = 2.260, ADX = 52.087) as for the 4th straigh week it is posting gains. This rally started on the first week of March when the stock almost touched the bottom of the 2 year Channel Up. This is a similar bullish wave to the one that started after the January 2024 bottom, which eventually reached the 1.236 Fibonacci extension. Aim for a bit under the top of the Channel Up (TP = 128.00. See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:XOMLong
by InvestingScope
2
ExxonMobil: Toward the ResistanceExxonMobil: Toward the Resistance As planned, XOM recently continued to rise with the magenta wave . We give this movement a bit more room, but another smaller corrective movement of wave should start below the resistance line at $126.34 before XOM ultimately surpasses this mark. Once the upward movement stalls below $126.34, it is important that the price doesn't fall too deeply afterward. After all, there is a 40% probability for our alternative scenario, where not wave in magenta but wave alt.2 in turquoise would develop its high – confirming an already established top of the overarching wave alt.(B) and, thus, a generally corrective scenario.
NYSE:XOM
by MarketIntel
Pendulum pick for KR - short tgt 44I have many tens of thousands of dollars worth of home renovations to do, so why not ask my dowsing/spirit team to help find me a stock that can help PAY for these expenses and then some? I'm a dowser, btw, so all my ideas & levels come from this form of information gathering. So woo woo ;) The pick is from all of NYSE, so it's a lot. I'll admit, when I've done this in the past I've seen stocks have way better moves faster & I'm like, "why didn't you give me THAT one?!" Regardless, I'm not going to disrespect the guidance, but just try to be more pointed in my intention. I did ask for this one to be a quick move, but I don't think it will be. I do, however, have good confidence the target will hit. I did not look at the chart before I finished the reading & had a target. It's a way to see how accurate the level & info might be, so I was definitely happy the chart & levels look reasonable. It's literally at a multi year high & the dowsing said it's at a swing high. Out the gate on this reading, it was saying swing trade short, & soon. It might get up to 69. Anyway, when I ask about the 44 level (tgt), twice I get that the "target is reached". I tried to get the amount of time this takes & got the months around May/June as an exit, but it could easily be a few months. It's a 36% drop from 69 if it reaches there. I drew the trendlines just to see how it behaves there. Maybe that'll help as a confirmation/trigger to short since it has been relatively strong. That's it. Hopefully, this can pay some bills!!
NYSE:KRShort
by JenRz
1
UPDATE: Level hold perfectly; you sold fear. New ATH is coming!Tesla is ready for a new ATH and potentially 20X even more. It's not only an EV cars company, as many wrongly see it. This is an update of my previous analysis, which received so much hate, but it doesn't change my view. I have added a massive amount at 22O, and it will be an amazing ride until the end of this decade. Here are the facts. They make more revenue in multiple sources than many people see I'm adding a graphical presentation from CernBasher (Tesla specialist) of how the Robotaxi and Optimus can be big. Yes, they might not reach the targets, but even if it's just half. It will be huge. Their Robotaxi business will rapidly outweigh the EV cars business in the near future. Now he has Trump and he will allow him all necessary licenses. and Tesla Optimus will even outperform the Robotaxi. Seems unreal, but the complexity of making a bot is easier than a car. They plan to run robot production faster than anything that has been ramped. The complexity of creating a bot is much less than a car. Also, once they start producing the bots, their factory will become more efficient. One bot can replace three people. The liquidity cycle is coming 🤔I think Optimus and Robotaxi will rapidly exceed their EV car revenue. Elon Musk is predicting over 1000% growth in 5 years. Which would be way above $2900 without stock splits. David Perk
NASDAQ:TSLALong
by David_Perk
33
VolitionRX | VNRX | Long at $0.54***Stay away if you are risk averse (small cap with 300-400k daily volume and could go to $0). VolitionRX AMEX:VNRX is a U.S.-based, multinational epigenetics company focused on developing blood tests for early disease detection, primarily targeting cancer and sepsis. Its Nu.Q blood tests are primarily for humans, focusing on early detection of diseases like cancer and sepsis. However, the company has also explored veterinary applications through its Nu.Q Vet product line, targeting cancer screening in animals, particularly dogs. Recent insider purchases got my attention, with the CEO and Director each grabbing $100k worth at $0.55. Plus, many other insiders have recently been awarded options. The company is making progress in signing multiple licensing deals for their Nu.Q platform in the human market, with strong interest from large companies. Many development milestones have been made within their cancer testing program and more are likely to be announced. However, the company is unprofitable at this time, and this is a highly risky / speculative play. It may take years to unfold or be a total disaster and go to $0.00. Rolling the dice at $0.54 with the goal to reach $0.75 and $1.00 in the coming 1-2 years. Analyst targets are in the $3.00-$3.50 range.
AMEX:VNRXLong
by WorthlessViews
Bullish set up is breaking out.... BUT, we have a gap to close.At the very moment we saw big rejection in this golden pocket zone were in right now from the descending channel its been in for a while. This tells me that the market makers are creating liquidity at this level potentially to revisit at a later date. We could quickly see this go to $6.35 or $5.40 which I would be a major buyer at. Still in the longer term bullish trend... for now. Option contract positions from institutions are primarily short at 5-6 strike. BUT something very interesting to me is that the $8.50 strike has a lot of puts at open interest which might squeeze it over that level if they have to cover.
NYSE:QBTSLong
by LeapTrades
FFIN Shortwe are probably marking the bottom by posting this. current US market conditions have prompted us to scout for shorts. FFIN provides us a classic (arguably) Heads & Shoulders pattern. a close above the right shoulder could invalidate the pattern. PT of $25.65 was derived by measuring the distance between the neckline and the head and transposing it to the downside. the bulls will rightly point out the fact that price is bouncing off support. the bear will counter by questioning the sustainability of the bounce .
NASDAQ:FFINShort
by Kwaku_As
APLD – 30-Min Long Trade Setup!📈 🔹 Ticker: APLD (NASDAQ) 🔹 Setup Type: Ascending Triangle + Resistance Break 🔸 Breakout Price: ~$5.80 📊 Trade Plan (Long Position) ✅ Entry Zone: $5.75–$5.85 (break above yellow resistance zone & trendline) ✅ Stop Loss (SL): Below $5.37 (structure low / white support line) ✅ Take Profit Targets: 📌 TP1: $6.25 (red line – resistance) 📌 TP2: $6.99 (green line – prior supply zone) 📐 Risk-Reward Analysis 📉 Risk: $5.80 - $5.37 = $0.43 📈 Reward to TP1: $6.25 - $5.80 = $0.45 → 1.04:1 R/R 📈 Reward to TP2: $6.99 - $5.80 = $1.19 → 2.76:1 R/R 🔍 Technical Highlights 📌 Ascending Triangle: Strong higher lows pushing into horizontal resistance 📌 Volume Confirmation: Needed for clean breakout 📌 Yellow Zone: Break and retest area for confirmation 📌 Trendline Support: Pink rising trendline continues to hold up price ⚙️ Trade Management 🔄 After TP1: — Move SL to breakeven — Book partial profits (~50%) 📈 Let the rest target TP2, trailing SL as new supports form ⚠️ Invalidation Signal ❌ Breakdown below $5.37 ❌ Rejection from yellow zone without volume follow-through
NASDAQ:APLDLong
by ProfittoPath
UXIN Longif our memory serves us correctly, UXIN was derived from a proprietary screen called "runner takes a breather." the screen in question looks to going, long on stocks that have experienced significant gains, after a reasonable pullback period. UXIN has been range-bound since we entered the position. we believe the next earnings date could serve as the much-needed catalyst. the leeway involved has kept us long the stock. we have done no fundamental work on this stock. thus, the catalyst is going to be a coin toss.
NASDAQ:UXINLong
by Kwaku_As
HCA Healthcare | HCA | Long at $299.00NYSE:HCA Healthcare: P/E of 13x, earnings are forecast to grow 6.01% per year; earnings have grown 10.6% per year over the past 5 years, and trading at good value compared to peers and industry. From a technical analysis perspective, it dipped to my selected historical simple moving average area and may represent a buying opportunity to fill the daily price gap up to $394.00. Thus, NYSE:HCA is in a personal buy zone at $299.00. Target #1 = $324.00 Target #2 = $362.00 Target #3 = $394.00
NYSE:HCALong
by WorthlessViews